|Mr. Peter G. Savas||Exec. Chairman and Chief Exec. Officer||401.62k||N/A||69|
|Mr. Kenneth L. Rice Jr., J.D., LLM, MBA||CFO, Principal Accounting Officer, Exec. VP of Fin. & Admin, Sec. and In-House Counsel||267.75k||N/A||62|
|Mr. Sam Martin||Director of Fin. and Corp. Compliance||N/A||N/A||N/A|
Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinsons disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.
Alseres Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.